nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CHRFAM7A—corpus luteum—uterine cancer	0.0578	0.208	CbGeAlD
Galantamine—CHRNA7—corpus luteum—uterine cancer	0.0467	0.168	CbGeAlD
Galantamine—CYP2D6—Progesterone—uterine cancer	0.0186	0.296	CbGbCtD
Galantamine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0178	0.284	CbGbCtD
Galantamine—CHRNA9—mammalian vulva—uterine cancer	0.0174	0.0624	CbGeAlD
Galantamine—CHRNG—myometrium—uterine cancer	0.0133	0.0478	CbGeAlD
Galantamine—CYP3A4—Progesterone—uterine cancer	0.0118	0.188	CbGbCtD
Galantamine—CHRNA5—vagina—uterine cancer	0.00981	0.0353	CbGeAlD
Galantamine—CHRNB2—myometrium—uterine cancer	0.0081	0.0291	CbGeAlD
Galantamine—CHRNA5—lymph node—uterine cancer	0.00635	0.0228	CbGeAlD
Galantamine—CHRNB2—uterine cervix—uterine cancer	0.0063	0.0227	CbGeAlD
Galantamine—CHRNB2—smooth muscle tissue—uterine cancer	0.00613	0.022	CbGeAlD
Galantamine—CHRNB2—decidua—uterine cancer	0.00601	0.0216	CbGeAlD
Galantamine—CHRNA10—vagina—uterine cancer	0.00594	0.0214	CbGeAlD
Galantamine—CHRNB2—endometrium—uterine cancer	0.0057	0.0205	CbGeAlD
Galantamine—CYP2D6—Doxorubicin—uterine cancer	0.00567	0.0903	CbGbCtD
Galantamine—CHRNB2—mammalian vulva—uterine cancer	0.00551	0.0198	CbGeAlD
Galantamine—CYP3A4—Etoposide—uterine cancer	0.00529	0.0842	CbGbCtD
Galantamine—CHRNB1—uterine cervix—uterine cancer	0.00529	0.019	CbGeAlD
Galantamine—CHRNB2—uterus—uterine cancer	0.00525	0.0189	CbGeAlD
Galantamine—CHRNB2—female gonad—uterine cancer	0.0043	0.0154	CbGeAlD
Galantamine—CHRNB2—vagina—uterine cancer	0.00427	0.0153	CbGeAlD
Galantamine—CHRNA10—lymph node—uterine cancer	0.00385	0.0138	CbGeAlD
Galantamine—CHRNA7—renal system—uterine cancer	0.00374	0.0134	CbGeAlD
Galantamine—CHRFAM7A—female reproductive system—uterine cancer	0.0037	0.0133	CbGeAlD
Galantamine—CYP3A4—Doxorubicin—uterine cancer	0.00361	0.0574	CbGbCtD
Galantamine—CHRNB1—female gonad—uterine cancer	0.0036	0.013	CbGeAlD
Galantamine—CHRNB1—vagina—uterine cancer	0.00358	0.0129	CbGeAlD
Galantamine—CHRFAM7A—female gonad—uterine cancer	0.00337	0.0121	CbGeAlD
Galantamine—CHRNA7—uterus—uterine cancer	0.00333	0.012	CbGeAlD
Galantamine—CHRNA7—female reproductive system—uterine cancer	0.00299	0.0108	CbGeAlD
Galantamine—BCHE—myometrium—uterine cancer	0.0029	0.0104	CbGeAlD
Galantamine—CHRNB2—lymph node—uterine cancer	0.00276	0.00993	CbGeAlD
Galantamine—CHRNA7—female gonad—uterine cancer	0.00272	0.00978	CbGeAlD
Galantamine—CHRNA3—lymph node—uterine cancer	0.00268	0.00963	CbGeAlD
Galantamine—CHRNB1—lymph node—uterine cancer	0.00232	0.00833	CbGeAlD
Galantamine—BCHE—uterine cervix—uterine cancer	0.00225	0.0081	CbGeAlD
Galantamine—BCHE—smooth muscle tissue—uterine cancer	0.00219	0.00787	CbGeAlD
Galantamine—BCHE—endometrium—uterine cancer	0.00204	0.00732	CbGeAlD
Galantamine—ACHE—lymph node—uterine cancer	0.00201	0.00722	CbGeAlD
Galantamine—BCHE—mammalian vulva—uterine cancer	0.00197	0.00708	CbGeAlD
Galantamine—BCHE—uterus—uterine cancer	0.00188	0.00675	CbGeAlD
Galantamine—BCHE—female reproductive system—uterine cancer	0.00169	0.00607	CbGeAlD
Galantamine—BCHE—vagina—uterine cancer	0.00153	0.00549	CbGeAlD
Galantamine—CYP3A4—renal system—uterine cancer	0.00142	0.0051	CbGeAlD
Galantamine—CYP2D6—renal system—uterine cancer	0.0014	0.00502	CbGeAlD
Galantamine—CYP3A4—female reproductive system—uterine cancer	0.00114	0.00408	CbGeAlD
Galantamine—CYP2D6—female reproductive system—uterine cancer	0.00112	0.00402	CbGeAlD
Galantamine—CYP2D6—female gonad—uterine cancer	0.00102	0.00366	CbGeAlD
Galantamine—BCHE—lymph node—uterine cancer	0.000988	0.00355	CbGeAlD
Galantamine—Nausea—Progesterone—uterine cancer	0.000782	0.00122	CcSEcCtD
Galantamine—Pain in extremity—Epirubicin—uterine cancer	0.000768	0.0012	CcSEcCtD
Galantamine—Feeling abnormal—Dactinomycin—uterine cancer	0.000767	0.00119	CcSEcCtD
Galantamine—Ill-defined disorder—Etoposide—uterine cancer	0.000766	0.00119	CcSEcCtD
Galantamine—Anaemia—Etoposide—uterine cancer	0.000763	0.00119	CcSEcCtD
Galantamine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000761	0.00119	CcSEcCtD
Galantamine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000759	0.00118	CcSEcCtD
Galantamine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000753	0.00117	CcSEcCtD
Galantamine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000752	0.00117	CcSEcCtD
Galantamine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000748	0.00116	CcSEcCtD
Galantamine—Renal impairment—Doxorubicin—uterine cancer	0.000747	0.00116	CcSEcCtD
Galantamine—Malaise—Etoposide—uterine cancer	0.000744	0.00116	CcSEcCtD
Galantamine—Vertigo—Etoposide—uterine cancer	0.000742	0.00115	CcSEcCtD
Galantamine—Purpura—Doxorubicin—uterine cancer	0.000738	0.00115	CcSEcCtD
Galantamine—Abdominal pain—Dactinomycin—uterine cancer	0.000736	0.00115	CcSEcCtD
Galantamine—Body temperature increased—Dactinomycin—uterine cancer	0.000736	0.00115	CcSEcCtD
Galantamine—Cardiac failure—Doxorubicin—uterine cancer	0.000729	0.00113	CcSEcCtD
Galantamine—Loss of consciousness—Etoposide—uterine cancer	0.000726	0.00113	CcSEcCtD
Galantamine—Lethargy—Doxorubicin—uterine cancer	0.000726	0.00113	CcSEcCtD
Galantamine—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000726	0.00113	CcSEcCtD
Galantamine—Ataxia—Epirubicin—uterine cancer	0.000723	0.00112	CcSEcCtD
Galantamine—Cough—Etoposide—uterine cancer	0.00072	0.00112	CcSEcCtD
Galantamine—Convulsion—Etoposide—uterine cancer	0.000715	0.00111	CcSEcCtD
Galantamine—Dehydration—Epirubicin—uterine cancer	0.000715	0.00111	CcSEcCtD
Galantamine—Hypertension—Etoposide—uterine cancer	0.000713	0.00111	CcSEcCtD
Galantamine—Pain in extremity—Doxorubicin—uterine cancer	0.000711	0.00111	CcSEcCtD
Galantamine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000709	0.0011	CcSEcCtD
Galantamine—Chest pain—Etoposide—uterine cancer	0.000703	0.00109	CcSEcCtD
Galantamine—Orthostatic hypotension—Epirubicin—uterine cancer	0.000702	0.00109	CcSEcCtD
Galantamine—Abdominal pain upper—Epirubicin—uterine cancer	0.000702	0.00109	CcSEcCtD
Galantamine—Hypokalaemia—Epirubicin—uterine cancer	0.000699	0.00109	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000698	0.00109	CcSEcCtD
Galantamine—Discomfort—Etoposide—uterine cancer	0.000694	0.00108	CcSEcCtD
Galantamine—Hypersensitivity—Dactinomycin—uterine cancer	0.000686	0.00107	CcSEcCtD
Galantamine—Gastritis—Epirubicin—uterine cancer	0.00068	0.00106	CcSEcCtD
Galantamine—Confusional state—Etoposide—uterine cancer	0.000679	0.00106	CcSEcCtD
Galantamine—Muscular weakness—Epirubicin—uterine cancer	0.000678	0.00106	CcSEcCtD
Galantamine—Ataxia—Doxorubicin—uterine cancer	0.000669	0.00104	CcSEcCtD
Galantamine—Asthenia—Dactinomycin—uterine cancer	0.000668	0.00104	CcSEcCtD
Galantamine—Dysphagia—Epirubicin—uterine cancer	0.000664	0.00103	CcSEcCtD
Galantamine—Dehydration—Doxorubicin—uterine cancer	0.000661	0.00103	CcSEcCtD
Galantamine—Thrombocytopenia—Etoposide—uterine cancer	0.00066	0.00103	CcSEcCtD
Galantamine—Tachycardia—Etoposide—uterine cancer	0.000658	0.00102	CcSEcCtD
Galantamine—Skin disorder—Etoposide—uterine cancer	0.000654	0.00102	CcSEcCtD
Galantamine—Hyperhidrosis—Etoposide—uterine cancer	0.000651	0.00101	CcSEcCtD
Galantamine—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000649	0.00101	CcSEcCtD
Galantamine—Abdominal pain upper—Doxorubicin—uterine cancer	0.000649	0.00101	CcSEcCtD
Galantamine—Hypokalaemia—Doxorubicin—uterine cancer	0.000647	0.00101	CcSEcCtD
Galantamine—Anorexia—Etoposide—uterine cancer	0.000642	0.001	CcSEcCtD
Galantamine—Bronchitis—Epirubicin—uterine cancer	0.000639	0.000994	CcSEcCtD
Galantamine—Diarrhoea—Dactinomycin—uterine cancer	0.000637	0.000992	CcSEcCtD
Galantamine—Hypotension—Etoposide—uterine cancer	0.00063	0.00098	CcSEcCtD
Galantamine—Gastritis—Doxorubicin—uterine cancer	0.000629	0.00098	CcSEcCtD
Galantamine—Muscular weakness—Doxorubicin—uterine cancer	0.000627	0.000976	CcSEcCtD
Galantamine—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000617	0.000961	CcSEcCtD
Galantamine—Dysphagia—Doxorubicin—uterine cancer	0.000615	0.000957	CcSEcCtD
Galantamine—Pollakiuria—Epirubicin—uterine cancer	0.000614	0.000955	CcSEcCtD
Galantamine—Paraesthesia—Etoposide—uterine cancer	0.000605	0.000942	CcSEcCtD
Galantamine—Weight decreased—Epirubicin—uterine cancer	0.000601	0.000935	CcSEcCtD
Galantamine—Hyperglycaemia—Epirubicin—uterine cancer	0.000599	0.000933	CcSEcCtD
Galantamine—Somnolence—Etoposide—uterine cancer	0.000599	0.000932	CcSEcCtD
Galantamine—Pneumonia—Epirubicin—uterine cancer	0.000596	0.000927	CcSEcCtD
Galantamine—Vomiting—Dactinomycin—uterine cancer	0.000592	0.000921	CcSEcCtD
Galantamine—Bronchitis—Doxorubicin—uterine cancer	0.000591	0.00092	CcSEcCtD
Galantamine—Rash—Dactinomycin—uterine cancer	0.000587	0.000914	CcSEcCtD
Galantamine—Decreased appetite—Etoposide—uterine cancer	0.000586	0.000912	CcSEcCtD
Galantamine—Renal failure—Epirubicin—uterine cancer	0.000582	0.000906	CcSEcCtD
Galantamine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000582	0.000906	CcSEcCtD
Galantamine—Fatigue—Etoposide—uterine cancer	0.000581	0.000904	CcSEcCtD
Galantamine—Neuropathy peripheral—Epirubicin—uterine cancer	0.00058	0.000904	CcSEcCtD
Galantamine—Constipation—Etoposide—uterine cancer	0.000576	0.000897	CcSEcCtD
Galantamine—Urinary tract infection—Epirubicin—uterine cancer	0.000576	0.000896	CcSEcCtD
Galantamine—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000571	0.000889	CcSEcCtD
Galantamine—Pollakiuria—Doxorubicin—uterine cancer	0.000568	0.000884	CcSEcCtD
Galantamine—Haematuria—Epirubicin—uterine cancer	0.000565	0.000879	CcSEcCtD
Galantamine—Hepatobiliary disease—Epirubicin—uterine cancer	0.00056	0.000872	CcSEcCtD
Galantamine—Epistaxis—Epirubicin—uterine cancer	0.000559	0.00087	CcSEcCtD
Galantamine—Weight decreased—Doxorubicin—uterine cancer	0.000556	0.000865	CcSEcCtD
Galantamine—Feeling abnormal—Etoposide—uterine cancer	0.000555	0.000864	CcSEcCtD
Galantamine—Hyperglycaemia—Doxorubicin—uterine cancer	0.000554	0.000863	CcSEcCtD
Galantamine—Nausea—Dactinomycin—uterine cancer	0.000553	0.000861	CcSEcCtD
Galantamine—Pneumonia—Doxorubicin—uterine cancer	0.000551	0.000858	CcSEcCtD
Galantamine—Gastrointestinal pain—Etoposide—uterine cancer	0.000551	0.000858	CcSEcCtD
Galantamine—Bradycardia—Epirubicin—uterine cancer	0.000541	0.000842	CcSEcCtD
Galantamine—Renal failure—Doxorubicin—uterine cancer	0.000539	0.000838	CcSEcCtD
Galantamine—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000537	0.000836	CcSEcCtD
Galantamine—Haemoglobin—Epirubicin—uterine cancer	0.000534	0.000832	CcSEcCtD
Galantamine—Rhinitis—Epirubicin—uterine cancer	0.000533	0.00083	CcSEcCtD
Galantamine—Abdominal pain—Etoposide—uterine cancer	0.000533	0.000829	CcSEcCtD
Galantamine—Body temperature increased—Etoposide—uterine cancer	0.000533	0.000829	CcSEcCtD
Galantamine—Urinary tract infection—Doxorubicin—uterine cancer	0.000533	0.000829	CcSEcCtD
Galantamine—Haemorrhage—Epirubicin—uterine cancer	0.000532	0.000828	CcSEcCtD
Galantamine—Hepatitis—Epirubicin—uterine cancer	0.000532	0.000828	CcSEcCtD
Galantamine—Urinary tract disorder—Epirubicin—uterine cancer	0.000525	0.000817	CcSEcCtD
Galantamine—Oedema peripheral—Epirubicin—uterine cancer	0.000524	0.000815	CcSEcCtD
Galantamine—Haematuria—Doxorubicin—uterine cancer	0.000522	0.000813	CcSEcCtD
Galantamine—Connective tissue disorder—Epirubicin—uterine cancer	0.000522	0.000813	CcSEcCtD
Galantamine—Urethral disorder—Epirubicin—uterine cancer	0.000521	0.000811	CcSEcCtD
Galantamine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000518	0.000807	CcSEcCtD
Galantamine—Epistaxis—Doxorubicin—uterine cancer	0.000517	0.000805	CcSEcCtD
Galantamine—Visual impairment—Epirubicin—uterine cancer	0.000512	0.000798	CcSEcCtD
Galantamine—Bradycardia—Doxorubicin—uterine cancer	0.000501	0.00078	CcSEcCtD
Galantamine—Eye disorder—Epirubicin—uterine cancer	0.000497	0.000773	CcSEcCtD
Galantamine—Hypersensitivity—Etoposide—uterine cancer	0.000496	0.000773	CcSEcCtD
Galantamine—Tinnitus—Epirubicin—uterine cancer	0.000496	0.000772	CcSEcCtD
Galantamine—Haemoglobin—Doxorubicin—uterine cancer	0.000494	0.00077	CcSEcCtD
Galantamine—Flushing—Epirubicin—uterine cancer	0.000493	0.000768	CcSEcCtD
Galantamine—Cardiac disorder—Epirubicin—uterine cancer	0.000493	0.000768	CcSEcCtD
Galantamine—Rhinitis—Doxorubicin—uterine cancer	0.000493	0.000768	CcSEcCtD
Galantamine—Hepatitis—Doxorubicin—uterine cancer	0.000492	0.000766	CcSEcCtD
Galantamine—Haemorrhage—Doxorubicin—uterine cancer	0.000492	0.000766	CcSEcCtD
Galantamine—Urinary tract disorder—Doxorubicin—uterine cancer	0.000486	0.000756	CcSEcCtD
Galantamine—Oedema peripheral—Doxorubicin—uterine cancer	0.000485	0.000754	CcSEcCtD
Galantamine—Asthenia—Etoposide—uterine cancer	0.000483	0.000753	CcSEcCtD
Galantamine—Connective tissue disorder—Doxorubicin—uterine cancer	0.000483	0.000752	CcSEcCtD
Galantamine—Angiopathy—Epirubicin—uterine cancer	0.000482	0.000751	CcSEcCtD
Galantamine—Urethral disorder—Doxorubicin—uterine cancer	0.000482	0.000751	CcSEcCtD
Galantamine—Immune system disorder—Epirubicin—uterine cancer	0.00048	0.000747	CcSEcCtD
Galantamine—Arrhythmia—Epirubicin—uterine cancer	0.000475	0.000739	CcSEcCtD
Galantamine—Visual impairment—Doxorubicin—uterine cancer	0.000474	0.000738	CcSEcCtD
Galantamine—Mental disorder—Epirubicin—uterine cancer	0.000466	0.000725	CcSEcCtD
Galantamine—Malnutrition—Epirubicin—uterine cancer	0.000463	0.00072	CcSEcCtD
Galantamine—Diarrhoea—Etoposide—uterine cancer	0.000461	0.000718	CcSEcCtD
Galantamine—Eye disorder—Doxorubicin—uterine cancer	0.00046	0.000716	CcSEcCtD
Galantamine—Tinnitus—Doxorubicin—uterine cancer	0.000459	0.000714	CcSEcCtD
Galantamine—Flushing—Doxorubicin—uterine cancer	0.000456	0.000711	CcSEcCtD
Galantamine—Cardiac disorder—Doxorubicin—uterine cancer	0.000456	0.000711	CcSEcCtD
Galantamine—Flatulence—Epirubicin—uterine cancer	0.000456	0.00071	CcSEcCtD
Galantamine—Tension—Epirubicin—uterine cancer	0.000454	0.000707	CcSEcCtD
Galantamine—Dysgeusia—Epirubicin—uterine cancer	0.000453	0.000705	CcSEcCtD
Galantamine—Nervousness—Epirubicin—uterine cancer	0.000449	0.0007	CcSEcCtD
Galantamine—Back pain—Epirubicin—uterine cancer	0.000448	0.000697	CcSEcCtD
Galantamine—Angiopathy—Doxorubicin—uterine cancer	0.000446	0.000695	CcSEcCtD
Galantamine—Dizziness—Etoposide—uterine cancer	0.000446	0.000694	CcSEcCtD
Galantamine—Muscle spasms—Epirubicin—uterine cancer	0.000445	0.000693	CcSEcCtD
Galantamine—Immune system disorder—Doxorubicin—uterine cancer	0.000444	0.000692	CcSEcCtD
Galantamine—Arrhythmia—Doxorubicin—uterine cancer	0.000439	0.000684	CcSEcCtD
Galantamine—Vision blurred—Epirubicin—uterine cancer	0.000436	0.000679	CcSEcCtD
Galantamine—Mental disorder—Doxorubicin—uterine cancer	0.000431	0.000671	CcSEcCtD
Galantamine—Ill-defined disorder—Epirubicin—uterine cancer	0.000429	0.000668	CcSEcCtD
Galantamine—Vomiting—Etoposide—uterine cancer	0.000428	0.000667	CcSEcCtD
Galantamine—Malnutrition—Doxorubicin—uterine cancer	0.000428	0.000667	CcSEcCtD
Galantamine—Anaemia—Epirubicin—uterine cancer	0.000428	0.000666	CcSEcCtD
Galantamine—Agitation—Epirubicin—uterine cancer	0.000425	0.000662	CcSEcCtD
Galantamine—Rash—Etoposide—uterine cancer	0.000425	0.000661	CcSEcCtD
Galantamine—Dermatitis—Etoposide—uterine cancer	0.000424	0.000661	CcSEcCtD
Galantamine—Headache—Etoposide—uterine cancer	0.000422	0.000657	CcSEcCtD
Galantamine—Flatulence—Doxorubicin—uterine cancer	0.000422	0.000657	CcSEcCtD
Galantamine—Tension—Doxorubicin—uterine cancer	0.00042	0.000654	CcSEcCtD
Galantamine—Dysgeusia—Doxorubicin—uterine cancer	0.000419	0.000653	CcSEcCtD
Galantamine—Malaise—Epirubicin—uterine cancer	0.000417	0.00065	CcSEcCtD
Galantamine—Nervousness—Doxorubicin—uterine cancer	0.000416	0.000647	CcSEcCtD
Galantamine—Vertigo—Epirubicin—uterine cancer	0.000416	0.000647	CcSEcCtD
Galantamine—Syncope—Epirubicin—uterine cancer	0.000415	0.000646	CcSEcCtD
Galantamine—Back pain—Doxorubicin—uterine cancer	0.000414	0.000645	CcSEcCtD
Galantamine—Muscle spasms—Doxorubicin—uterine cancer	0.000412	0.000641	CcSEcCtD
Galantamine—Palpitations—Epirubicin—uterine cancer	0.000409	0.000637	CcSEcCtD
Galantamine—Loss of consciousness—Epirubicin—uterine cancer	0.000407	0.000633	CcSEcCtD
Galantamine—Cough—Epirubicin—uterine cancer	0.000404	0.000629	CcSEcCtD
Galantamine—Vision blurred—Doxorubicin—uterine cancer	0.000404	0.000628	CcSEcCtD
Galantamine—Convulsion—Epirubicin—uterine cancer	0.000401	0.000624	CcSEcCtD
Galantamine—Nausea—Etoposide—uterine cancer	0.0004	0.000623	CcSEcCtD
Galantamine—Hypertension—Epirubicin—uterine cancer	0.0004	0.000622	CcSEcCtD
Galantamine—Ill-defined disorder—Doxorubicin—uterine cancer	0.000397	0.000618	CcSEcCtD
Galantamine—Anaemia—Doxorubicin—uterine cancer	0.000396	0.000616	CcSEcCtD
Galantamine—Chest pain—Epirubicin—uterine cancer	0.000394	0.000613	CcSEcCtD
Galantamine—Myalgia—Epirubicin—uterine cancer	0.000394	0.000613	CcSEcCtD
Galantamine—Arthralgia—Epirubicin—uterine cancer	0.000394	0.000613	CcSEcCtD
Galantamine—Agitation—Doxorubicin—uterine cancer	0.000393	0.000613	CcSEcCtD
Galantamine—Anxiety—Epirubicin—uterine cancer	0.000393	0.000611	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000391	0.000609	CcSEcCtD
Galantamine—Discomfort—Epirubicin—uterine cancer	0.000389	0.000606	CcSEcCtD
Galantamine—Malaise—Doxorubicin—uterine cancer	0.000386	0.000601	CcSEcCtD
Galantamine—Dry mouth—Epirubicin—uterine cancer	0.000385	0.0006	CcSEcCtD
Galantamine—Vertigo—Doxorubicin—uterine cancer	0.000385	0.000599	CcSEcCtD
Galantamine—Syncope—Doxorubicin—uterine cancer	0.000384	0.000598	CcSEcCtD
Galantamine—Confusional state—Epirubicin—uterine cancer	0.000381	0.000593	CcSEcCtD
Galantamine—Palpitations—Doxorubicin—uterine cancer	0.000378	0.000589	CcSEcCtD
Galantamine—Loss of consciousness—Doxorubicin—uterine cancer	0.000376	0.000586	CcSEcCtD
Galantamine—Cough—Doxorubicin—uterine cancer	0.000374	0.000582	CcSEcCtD
Galantamine—Shock—Epirubicin—uterine cancer	0.000372	0.000578	CcSEcCtD
Galantamine—Convulsion—Doxorubicin—uterine cancer	0.000371	0.000578	CcSEcCtD
Galantamine—Nervous system disorder—Epirubicin—uterine cancer	0.00037	0.000577	CcSEcCtD
Galantamine—Thrombocytopenia—Epirubicin—uterine cancer	0.00037	0.000576	CcSEcCtD
Galantamine—Hypertension—Doxorubicin—uterine cancer	0.00037	0.000575	CcSEcCtD
Galantamine—Tachycardia—Epirubicin—uterine cancer	0.000369	0.000574	CcSEcCtD
Galantamine—Skin disorder—Epirubicin—uterine cancer	0.000367	0.000571	CcSEcCtD
Galantamine—Hyperhidrosis—Epirubicin—uterine cancer	0.000365	0.000568	CcSEcCtD
Galantamine—Chest pain—Doxorubicin—uterine cancer	0.000365	0.000567	CcSEcCtD
Galantamine—Arthralgia—Doxorubicin—uterine cancer	0.000365	0.000567	CcSEcCtD
Galantamine—Myalgia—Doxorubicin—uterine cancer	0.000365	0.000567	CcSEcCtD
Galantamine—Anxiety—Doxorubicin—uterine cancer	0.000363	0.000566	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000362	0.000564	CcSEcCtD
Galantamine—Discomfort—Doxorubicin—uterine cancer	0.00036	0.000561	CcSEcCtD
Galantamine—Anorexia—Epirubicin—uterine cancer	0.00036	0.00056	CcSEcCtD
Galantamine—Dry mouth—Doxorubicin—uterine cancer	0.000357	0.000555	CcSEcCtD
Galantamine—Hypotension—Epirubicin—uterine cancer	0.000353	0.000549	CcSEcCtD
Galantamine—Confusional state—Doxorubicin—uterine cancer	0.000352	0.000549	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000344	0.000536	CcSEcCtD
Galantamine—Shock—Doxorubicin—uterine cancer	0.000344	0.000535	CcSEcCtD
Galantamine—Nervous system disorder—Doxorubicin—uterine cancer	0.000343	0.000534	CcSEcCtD
Galantamine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000342	0.000533	CcSEcCtD
Galantamine—Insomnia—Epirubicin—uterine cancer	0.000342	0.000532	CcSEcCtD
Galantamine—Tachycardia—Doxorubicin—uterine cancer	0.000341	0.000531	CcSEcCtD
Galantamine—Skin disorder—Doxorubicin—uterine cancer	0.000339	0.000528	CcSEcCtD
Galantamine—Paraesthesia—Epirubicin—uterine cancer	0.000339	0.000528	CcSEcCtD
Galantamine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000338	0.000526	CcSEcCtD
Galantamine—Somnolence—Epirubicin—uterine cancer	0.000336	0.000523	CcSEcCtD
Galantamine—Anorexia—Doxorubicin—uterine cancer	0.000333	0.000519	CcSEcCtD
Galantamine—Dyspepsia—Epirubicin—uterine cancer	0.000332	0.000518	CcSEcCtD
Galantamine—Decreased appetite—Epirubicin—uterine cancer	0.000328	0.000511	CcSEcCtD
Galantamine—Hypotension—Doxorubicin—uterine cancer	0.000327	0.000508	CcSEcCtD
Galantamine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000326	0.000508	CcSEcCtD
Galantamine—Fatigue—Epirubicin—uterine cancer	0.000326	0.000507	CcSEcCtD
Galantamine—Constipation—Epirubicin—uterine cancer	0.000323	0.000503	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000318	0.000496	CcSEcCtD
Galantamine—Insomnia—Doxorubicin—uterine cancer	0.000316	0.000492	CcSEcCtD
Galantamine—Paraesthesia—Doxorubicin—uterine cancer	0.000314	0.000488	CcSEcCtD
Galantamine—Feeling abnormal—Epirubicin—uterine cancer	0.000311	0.000485	CcSEcCtD
Galantamine—Somnolence—Doxorubicin—uterine cancer	0.000311	0.000484	CcSEcCtD
Galantamine—Gastrointestinal pain—Epirubicin—uterine cancer	0.000309	0.000481	CcSEcCtD
Galantamine—Dyspepsia—Doxorubicin—uterine cancer	0.000308	0.000479	CcSEcCtD
Galantamine—Decreased appetite—Doxorubicin—uterine cancer	0.000304	0.000473	CcSEcCtD
Galantamine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000302	0.00047	CcSEcCtD
Galantamine—Fatigue—Doxorubicin—uterine cancer	0.000301	0.000469	CcSEcCtD
Galantamine—Constipation—Doxorubicin—uterine cancer	0.000299	0.000465	CcSEcCtD
Galantamine—Body temperature increased—Epirubicin—uterine cancer	0.000299	0.000465	CcSEcCtD
Galantamine—Abdominal pain—Epirubicin—uterine cancer	0.000299	0.000465	CcSEcCtD
Galantamine—Feeling abnormal—Doxorubicin—uterine cancer	0.000288	0.000448	CcSEcCtD
Galantamine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000286	0.000445	CcSEcCtD
Galantamine—Hypersensitivity—Epirubicin—uterine cancer	0.000278	0.000433	CcSEcCtD
Galantamine—Abdominal pain—Doxorubicin—uterine cancer	0.000276	0.00043	CcSEcCtD
Galantamine—Body temperature increased—Doxorubicin—uterine cancer	0.000276	0.00043	CcSEcCtD
Galantamine—Asthenia—Epirubicin—uterine cancer	0.000271	0.000422	CcSEcCtD
Galantamine—Diarrhoea—Epirubicin—uterine cancer	0.000258	0.000402	CcSEcCtD
Galantamine—Hypersensitivity—Doxorubicin—uterine cancer	0.000257	0.000401	CcSEcCtD
Galantamine—Asthenia—Doxorubicin—uterine cancer	0.000251	0.00039	CcSEcCtD
Galantamine—Dizziness—Epirubicin—uterine cancer	0.00025	0.000389	CcSEcCtD
Galantamine—Vomiting—Epirubicin—uterine cancer	0.00024	0.000374	CcSEcCtD
Galantamine—Diarrhoea—Doxorubicin—uterine cancer	0.000239	0.000372	CcSEcCtD
Galantamine—Rash—Epirubicin—uterine cancer	0.000238	0.000371	CcSEcCtD
Galantamine—Dermatitis—Epirubicin—uterine cancer	0.000238	0.00037	CcSEcCtD
Galantamine—Headache—Epirubicin—uterine cancer	0.000237	0.000368	CcSEcCtD
Galantamine—Dizziness—Doxorubicin—uterine cancer	0.000231	0.00036	CcSEcCtD
Galantamine—Nausea—Epirubicin—uterine cancer	0.000224	0.000349	CcSEcCtD
Galantamine—Vomiting—Doxorubicin—uterine cancer	0.000222	0.000346	CcSEcCtD
Galantamine—Rash—Doxorubicin—uterine cancer	0.00022	0.000343	CcSEcCtD
Galantamine—Dermatitis—Doxorubicin—uterine cancer	0.00022	0.000343	CcSEcCtD
Galantamine—Headache—Doxorubicin—uterine cancer	0.000219	0.000341	CcSEcCtD
Galantamine—Nausea—Doxorubicin—uterine cancer	0.000208	0.000323	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000197	0.0119	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000193	0.0117	CbGpPWpGaD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—HRAS—uterine cancer	0.000188	0.0113	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—INHBA—uterine cancer	0.000187	0.0113	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—ABCC9—uterine cancer	0.00018	0.0109	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—MME—uterine cancer	0.000176	0.0106	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—ABCC9—uterine cancer	0.000171	0.0103	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—EZH2—uterine cancer	0.00017	0.0103	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—ERBB2—uterine cancer	0.000169	0.0102	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—ABCC9—uterine cancer	0.000169	0.0102	CbGpPWpGaD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—AKT1—uterine cancer	0.000166	0.01	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000165	0.00996	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—ABCC9—uterine cancer	0.000161	0.00972	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000152	0.00919	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000143	0.00864	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—SOCS3—uterine cancer	0.000142	0.00859	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—ABCC9—uterine cancer	0.000139	0.00843	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000132	0.00798	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—NRAS—uterine cancer	0.000129	0.00779	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000117	0.00705	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—KRAS—uterine cancer	0.000111	0.0067	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.00011	0.00663	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000108	0.0065	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—PIK3CA—uterine cancer	0.000102	0.00616	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—ESR1—uterine cancer	0.000101	0.00612	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—ABCC9—uterine cancer	9.95e-05	0.00601	CbGpPWpGaD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	9.45e-05	0.00571	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—HRAS—uterine cancer	9.43e-05	0.0057	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—ABCC9—uterine cancer	8.88e-05	0.00536	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TSPYL2—uterine cancer	8.87e-05	0.00536	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	8.35e-05	0.00504	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—AKT1—uterine cancer	8.33e-05	0.00503	CbGpPWpGaD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	8.26e-05	0.00499	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	8.24e-05	0.00498	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—CXCL8—uterine cancer	8.16e-05	0.00493	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TSPYL2—uterine cancer	7.92e-05	0.00478	CbGpPWpGaD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	7.83e-05	0.00473	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	7.78e-05	0.0047	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	7.53e-05	0.00455	CbGpPWpGaD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	7.47e-05	0.00451	CbGpPWpGaD
Galantamine—CHRNA9—Transmission across Chemical Synapses—HRAS—uterine cancer	7.1e-05	0.00429	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—CXCL8—uterine cancer	7.06e-05	0.00426	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	7.05e-05	0.00426	CbGpPWpGaD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	7.02e-05	0.00424	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—EP300—uterine cancer	7e-05	0.00423	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	6.94e-05	0.00419	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.77e-05	0.00409	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—VEGFA—uterine cancer	6.63e-05	0.004	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	6.53e-05	0.00395	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CXCL8—uterine cancer	6.42e-05	0.00388	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—AKR1B10—uterine cancer	6.38e-05	0.00385	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—HRAS—uterine cancer	6.21e-05	0.00375	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.14e-05	0.00371	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.06e-05	0.00366	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—EP300—uterine cancer	6.05e-05	0.00366	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—PTEN—uterine cancer	5.99e-05	0.00362	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	5.93e-05	0.00358	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	5.93e-05	0.00358	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—AKR1B1—uterine cancer	5.93e-05	0.00358	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	5.93e-05	0.00358	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—HRAS—uterine cancer	5.88e-05	0.00355	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—EP300—uterine cancer	5.71e-05	0.00345	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.63e-05	0.0034	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.63e-05	0.0034	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—HRAS—uterine cancer	5.61e-05	0.00339	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CXCL8—uterine cancer	5.58e-05	0.00337	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—EP300—uterine cancer	5.51e-05	0.00333	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	5.46e-05	0.0033	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—HRAS—uterine cancer	5.44e-05	0.00329	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	5.39e-05	0.00325	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	5.32e-05	0.00321	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—HRAS—uterine cancer	5.28e-05	0.00319	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	5.22e-05	0.00315	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—VEGFA—uterine cancer	5.22e-05	0.00315	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	5.14e-05	0.00311	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.02e-05	0.00303	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.02e-05	0.00303	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.98e-05	0.00301	CbGpPWpGaD
Galantamine—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	4.97e-05	0.003	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—CTNNB1—uterine cancer	4.86e-05	0.00294	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—EP300—uterine cancer	4.78e-05	0.00289	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—HRAS—uterine cancer	4.76e-05	0.00287	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CXCL8—uterine cancer	4.55e-05	0.00275	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—VEGFA—uterine cancer	4.53e-05	0.00274	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—HRAS—uterine cancer	4.51e-05	0.00272	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—HRAS—uterine cancer	4.46e-05	0.00269	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	4.43e-05	0.00267	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—AKR1C1—uterine cancer	4.35e-05	0.00263	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—CTNNB1—uterine cancer	4.34e-05	0.00262	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—HRAS—uterine cancer	4.3e-05	0.0026	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	4.19e-05	0.00253	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	4.17e-05	0.00252	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	4.15e-05	0.00251	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.13e-05	0.00249	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	4.11e-05	0.00248	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—uterine cancer	4.09e-05	0.00247	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—HRAS—uterine cancer	4.04e-05	0.00244	CbGpPWpGaD
Galantamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.02e-05	0.00243	CbGpPWpGaD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	3.96e-05	0.00239	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—INHBA—uterine cancer	3.96e-05	0.00239	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	3.96e-05	0.00239	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—HRAS—uterine cancer	3.93e-05	0.00237	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—EP300—uterine cancer	3.9e-05	0.00235	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	3.88e-05	0.00234	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GPX3—uterine cancer	3.82e-05	0.00231	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.76e-05	0.00227	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—MME—uterine cancer	3.73e-05	0.00225	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—VEGFA—uterine cancer	3.69e-05	0.00223	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.68e-05	0.00223	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP11A1—uterine cancer	3.6e-05	0.00217	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.57e-05	0.00216	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP11A1—uterine cancer	3.55e-05	0.00214	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—INHBA—uterine cancer	3.54e-05	0.00214	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.53e-05	0.00213	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NDUFB11—uterine cancer	3.47e-05	0.00209	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SRD5A2—uterine cancer	3.47e-05	0.00209	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—HRAS—uterine cancer	3.42e-05	0.00206	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.37e-05	0.00203	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.35e-05	0.00203	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	3.35e-05	0.00202	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—MME—uterine cancer	3.32e-05	0.00201	CbGpPWpGaD
Galantamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.26e-05	0.00197	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PTEN—uterine cancer	3.22e-05	0.00194	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.18e-05	0.00192	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—HRAS—uterine cancer	3.12e-05	0.00189	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NDUFB11—uterine cancer	3.09e-05	0.00187	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SRD5A2—uterine cancer	3.09e-05	0.00187	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—HRAS—uterine cancer	3.09e-05	0.00187	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—HRAS—uterine cancer	3.01e-05	0.00182	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3e-05	0.00181	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.91e-05	0.00176	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.91e-05	0.00176	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PTEN—uterine cancer	2.87e-05	0.00173	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	2.84e-05	0.00172	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.84e-05	0.00171	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—HRAS—uterine cancer	2.83e-05	0.00171	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.69e-05	0.00163	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—HRAS—uterine cancer	2.68e-05	0.00162	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—HRAS—uterine cancer	2.65e-05	0.0016	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	2.65e-05	0.0016	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	2.61e-05	0.00158	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.54e-05	0.00154	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—HRAS—uterine cancer	2.52e-05	0.00152	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKR1B1—uterine cancer	2.51e-05	0.00151	CbGpPWpGaD
Galantamine—ACHE—Metabolism—STAR—uterine cancer	2.51e-05	0.00151	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	2.5e-05	0.00151	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.48e-05	0.0015	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.48e-05	0.0015	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—FBXW7—uterine cancer	2.45e-05	0.00148	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—HRAS—uterine cancer	2.39e-05	0.00144	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—HRAS—uterine cancer	2.37e-05	0.00143	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.36e-05	0.00143	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	2.35e-05	0.00142	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	2.32e-05	0.0014	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—PIK3CA—uterine cancer	2.27e-05	0.00137	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.24e-05	0.00135	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKR1B1—uterine cancer	2.24e-05	0.00135	CbGpPWpGaD
Galantamine—BCHE—Metabolism—STAR—uterine cancer	2.24e-05	0.00135	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.21e-05	0.00133	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.19e-05	0.00132	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—HRAS—uterine cancer	2.19e-05	0.00132	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—FBXW7—uterine cancer	2.18e-05	0.00132	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—HRAS—uterine cancer	2.17e-05	0.00131	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—HRAS—uterine cancer	2.06e-05	0.00124	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—HRAS—uterine cancer	2.03e-05	0.00123	CbGpPWpGaD
Galantamine—BCHE—Phospholipid metabolism—PIK3CA—uterine cancer	2.02e-05	0.00122	CbGpPWpGaD
Galantamine—ACHE—Metabolism—POLD1—uterine cancer	1.97e-05	0.00119	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—HRAS—uterine cancer	1.93e-05	0.00117	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.9e-05	0.00115	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKR1C1—uterine cancer	1.84e-05	0.00111	CbGpPWpGaD
Galantamine—BCHE—Metabolism—POLD1—uterine cancer	1.75e-05	0.00106	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.75e-05	0.00106	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.73e-05	0.00104	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.71e-05	0.00103	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.69e-05	0.00102	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—HRAS—uterine cancer	1.68e-05	0.00101	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKR1C1—uterine cancer	1.64e-05	0.000991	CbGpPWpGaD
Galantamine—ACHE—Metabolism—RRM2—uterine cancer	1.64e-05	0.00099	CbGpPWpGaD
Galantamine—ACHE—Metabolism—DCN—uterine cancer	1.59e-05	0.000961	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—HRAS—uterine cancer	1.56e-05	0.000942	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP11A1—uterine cancer	1.5e-05	0.000906	CbGpPWpGaD
Galantamine—BCHE—Metabolism—RRM2—uterine cancer	1.46e-05	0.000883	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.43e-05	0.000863	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NDUFB11—uterine cancer	1.42e-05	0.000859	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SRD5A2—uterine cancer	1.42e-05	0.000859	CbGpPWpGaD
Galantamine—BCHE—Metabolism—DCN—uterine cancer	1.42e-05	0.000858	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKR1C3—uterine cancer	1.42e-05	0.000855	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—HRAS—uterine cancer	1.39e-05	0.000841	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP11A1—uterine cancer	1.34e-05	0.000808	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKR1C3—uterine cancer	1.26e-05	0.000763	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CCL2—uterine cancer	1.26e-05	0.00076	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—HRAS—uterine cancer	1.2e-05	0.000722	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CCL2—uterine cancer	1.12e-05	0.000678	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP19A1—uterine cancer	1.1e-05	0.000666	CbGpPWpGaD
Galantamine—ACHE—Metabolism—STK11—uterine cancer	1.1e-05	0.000666	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—HRAS—uterine cancer	1.07e-05	0.000644	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.04e-05	0.000625	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.03e-05	0.000621	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—STAR—uterine cancer	1.03e-05	0.000621	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CXCL8—uterine cancer	9.95e-06	0.000601	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.88e-06	0.000596	CbGpPWpGaD
Galantamine—BCHE—Metabolism—STK11—uterine cancer	9.84e-06	0.000594	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP19A1—uterine cancer	9.84e-06	0.000594	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NDUFB11—uterine cancer	9.3e-06	0.000561	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SRD5A2—uterine cancer	9.3e-06	0.000561	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.24e-06	0.000558	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—CTNNB1—uterine cancer	9.18e-06	0.000554	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CXCL8—uterine cancer	8.88e-06	0.000536	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.81e-06	0.000532	CbGpPWpGaD
Galantamine—ACHE—Metabolism—MTHFR—uterine cancer	8.29e-06	0.000501	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—CTNNB1—uterine cancer	8.19e-06	0.000495	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—POLD1—uterine cancer	8.07e-06	0.000487	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKR1C1—uterine cancer	7.54e-06	0.000456	CbGpPWpGaD
Galantamine—BCHE—Metabolism—MTHFR—uterine cancer	7.4e-06	0.000447	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.31e-06	0.000441	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—RRM2—uterine cancer	6.72e-06	0.000406	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—STAR—uterine cancer	6.72e-06	0.000406	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKR1B1—uterine cancer	6.72e-06	0.000406	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—DCN—uterine cancer	6.53e-06	0.000394	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.52e-06	0.000394	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP11A1—uterine cancer	6.15e-06	0.000371	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKR1C3—uterine cancer	5.81e-06	0.000351	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—POLD1—uterine cancer	5.27e-06	0.000319	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKR1C1—uterine cancer	4.93e-06	0.000298	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTEN—uterine cancer	4.61e-06	0.000279	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP19A1—uterine cancer	4.52e-06	0.000273	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—STK11—uterine cancer	4.52e-06	0.000273	CbGpPWpGaD
Galantamine—ACHE—Metabolism—EP300—uterine cancer	4.4e-06	0.000266	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—RRM2—uterine cancer	4.4e-06	0.000266	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—DCN—uterine cancer	4.27e-06	0.000258	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTEN—uterine cancer	4.11e-06	0.000248	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.02e-06	0.000243	CbGpPWpGaD
Galantamine—BCHE—Metabolism—EP300—uterine cancer	3.92e-06	0.000237	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKR1C3—uterine cancer	3.8e-06	0.000229	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—MTHFR—uterine cancer	3.4e-06	0.000205	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PIK3CA—uterine cancer	3.25e-06	0.000197	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—STK11—uterine cancer	2.96e-06	0.000179	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.96e-06	0.000179	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PIK3CA—uterine cancer	2.9e-06	0.000175	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKT1—uterine cancer	2.66e-06	0.000161	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKT1—uterine cancer	2.37e-06	0.000143	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—MTHFR—uterine cancer	2.22e-06	0.000134	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTEN—uterine cancer	1.89e-06	0.000114	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—EP300—uterine cancer	1.8e-06	0.000109	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.33e-06	8.06e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTEN—uterine cancer	1.24e-06	7.47e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—EP300—uterine cancer	1.18e-06	7.12e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKT1—uterine cancer	1.09e-06	6.58e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PIK3CA—uterine cancer	8.72e-07	5.27e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKT1—uterine cancer	7.13e-07	4.3e-05	CbGpPWpGaD
